Biocon Secures Global Market Entry for Biosimilar Yesintek Through Janssen Licensing Agreement
Biocon Ltd 路 Others (Uncategorized) 路 26 Oct 2026, 1:57 pm
Biocon Secures Global Market Entry for Biosimilar Yesintek Through Janssen Licensing Agreement Biocon Limited has entered into a licensing agreement with Janssen Sciences Ireland, enabling immediate commercialization rights for Yesintek (a proposed biosimilar to Ustekinumab / Stelara) across Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea, and Kazakhstan, subject to regulatory approvals. This expands upon prior agreements covering the US, Europe, UK, Canada, and Japan. Yesintek targets autoimmune indications including Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Reference drug Stelara recorded global sales of $6.08 billion in 2025.
Original exchange filing (PDF)
More announcements from Biocon Ltd
- Press Release 路 18 Nov 2026
- Press Release 路 16 Nov 2026
- Intimation on Schedule of Meetings with Analyst(s)/institutional Investor(s) 路 12 Nov 2026
- Earnings Call Transcript for Q2 FY27 路 12 Nov 2026
- Audio and Video Recording of Q2 FY27 Earnings Call 路 05 Nov 2026
- Communication regarding withholding of final dividend for the FY 2025-26 路 04 Nov 2026
- Investor Presentation 路 04 Nov 2026
- Change in Senior Management Personnel 路 04 Nov 2026
